Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Scientists have built a first-of-its-kind spatial multiomics atlas of chronic kidney transplant injury, revealing that fibrosis isn't a one-size-fits-all process. Different kidney regions scar through distinct cellular and metabolic mechanisms — and blocking a key metabolic pathway showed early promise in slowing the damage. The findings could open new doors for targeted therapies to improve long-term transplant survival.
Long-term kidney transplant survival is a persistent challenge in medicine, with chronic allograft dysfunction (CAD) and the resulting fibrosis (scarring) being major culprits. A new study from Beijing Institute of Technology takes a deep dive into why this happens — and the answer turns out to be more nuanced than previously thought.
Using a combination of mouse and human tissue data — including single-cell RNA sequencing, spatial transcriptomics, and spatial metabolomics — researchers constructed a comprehensive spatial multiomics atlas of chronic kidney allograft injury. The atlas maps not just what cells are present, but where they are and how they're behaving metabolically.
The big finding: fibrosis looks very different depending on where in the kidney it occurs. In the cortex, scarring is tied to changes in blood vessel-lining cells and altered cholesterol metabolism. In the medulla, a different story unfolds — tubular cells shift toward glycolysis (sugar-burning), and nearby immune T-cells show signs of exhaustion. Notably, blocking glycolysis with a drug called 2-DG partially reversed some of these damaging changes in lab experiments.
Key Takeaways:
Why it matters: This atlas gives researchers a detailed roadmap of the regional biology driving kidney transplant failure — and hints at metabolic pathways that could one day be targeted to extend graft survival for the hundreds of thousands of patients who depend on transplanted kidneys.